Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;14(1):21-29.
doi: 10.1038/nrcardio.2016.166. Epub 2016 Oct 20.

Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease

Affiliations
Review

Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease

Gerard Pasterkamp et al. Nat Rev Cardiol. 2017 Jan.

Abstract

The concept of the 'vulnerable plaque' originated from pathological observations in patients who died from acute coronary syndrome. This recognition spawned a generation of research that led to greater understanding of how complicated atherosclerotic plaques form and precipitate thrombotic events. In current practice, an increasing number of patients who survive their first event present with non-ST-segment elevation myocardial infarction (NSTEMI) rather than myocardial infarction (MI) with ST-segment elevation (STEMI). The culprit lesions that provide the pathological substrate for NSTEMI can vary considerably from the so-called 'vulnerable plaque'. The shift in clinical presentation of MI and stroke corresponds temporally to a progressive change in the characteristics of human plaques away from the supposed characteristics of vulnerability. These alterations in the structure and function of human atherosclerotic lesions might mirror the modifications that are produced in experimental plaques by lipid lowering, inspired by the vulnerable plaque construct. The shift in the clinical presentations of the acute coronary syndromes mandates a critical reassessment of the underlying mechanisms, proposed risk scores, the results and interpretation of preclinical experiments, as well as recognition of the limitations of the use of population data and samples collected before the application of current preventive interventions.

PubMed Disclaimer

References

    1. Circulation. 1996 Apr 1;93(7):1354-63 - PubMed
    1. Int J Cardiol. 2013 Oct 15;168(6):5126-34 - PubMed
    1. Circulation. 2007 Feb 20;115(7):928-35 - PubMed
    1. JAMA Cardiol. 2016 Jul 1;1(4):397-404 - PubMed
    1. Annu Rev Public Health. 2011;32:5-22 - PubMed

MeSH terms